Synthetic Biology: Engineering Living Systems

Introduction to Synthetic Biology

Synthetic biology applies engineering principles—standardisation, modularity, abstraction, and iterative design-build-test cycles—to design and construct novel biological parts, circuits, and systems. Building on molecular biology and genetic engineering foundations, synthetic biology moves beyond modifying existing biology to constructing entirely new biological functions or organisms. Since landmark demonstrations of programmable genetic circuits (the genetic toggle switch and repressilator in 2000), the field has expanded to tackle biosensor design, metabolic engineering, cell therapy programming, biomanufacturing, and environmental applications.

Key concepts in synthetic biology include standardised biological parts (BioBrick registry of characterised genetic components—promoters, ribosome binding sites, coding sequences, terminators), orthogonal (non-cross-reacting) molecular tools, chassis organisms (well-characterised hosts for circuit deployment—E. coli, S. cerevisiae, CHO cells), and quantitative forward design of genetic circuits with predictable behaviour. Advances in DNA synthesis, CRISPR-based genome editing, and computational design now enable construction of complex genetic circuits across the genome with increasing reliability, moving from proof-of-concept demonstrations to industrial and clinical applications.

Genetic Circuits and Logic Gates

Toggle Switches and Memory

Gardner's genetic toggle switch (2000) constructed two mutually repressing transcription factor genes in an E. coli plasmid. Either repressor can dominate depending on initial conditions and external signals; the system exhibits bistability—switching between two stable states and maintaining memory of the switch trigger after signal removal. Biological memory circuits enable cells to record exposure to a signal, integrate multiple signals over time, or maintain different gene expression programs in genetically identical cells. Applications include lineage tracing in development (marking cells that experienced a specific signal), biosensing of past environmental exposures, and cell therapy with programmable decision-making.

Boolean Logic in Cells

Synthetic gene circuits can implement Boolean logic operations using engineered transcription factors or RNA regulators. AND gates activate output only when both inputs are present (e.g., promoter requiring two transcription factors). OR gates activate with either input; NOT gates invert input signals. Multi-layer circuits combining logic gates implement complex if-then-else decision trees in living cells. RNA-based logic gates using ribozymes, toe-hold switches, and CRISPRi/a enable rapid programmable logic in mammalian cells. CAR-T cells are being engineered with AND logic requiring both tumour antigen A AND B for activation—reducing on-target off-tumour toxicity through two-antigen specificity.

Metabolic Engineering

Biosynthesis of High-Value Compounds

Synthetic biology refactors and extends metabolic pathways in microorganisms to produce valuable compounds—pharmaceuticals, biofuels, materials. Artemisinic acid production in S. cerevisiae (Jay Keasling, UC Berkeley) engineered 12 genes including the artemisinin synthase from Artemisia annua into yeast, achieving commercial-scale anti-malarial artemisinin production independent of plant cultivation variability—reducing production cost by 90%. Taxol precursor production in E. coli and S. cerevisiae is demonstrated at research scale. Shikonin dyes, resveratrol, vanillin, and many other compounds previously extracted from plants or purified from chemical synthesis are produced more sustainably by engineered microorganisms.

Next-Generation Biofuels

Advanced biofuels with better fuel properties than ethanol—isobutanol, fatty acid ethyl esters, alkanes—are produced by engineered E. coli and yeast. Engineering strategies include eliminating competing pathways, overexpressing rate-limiting enzymes (identified by metabolic flux analysis), co-factor balancing (ensuring NADPH availability for biosynthetic reactions), and product tolerance (many biofuels are toxic to producing organisms at high concentrations—engineering membrane composition, efflux pumps, and stress responses improves titres). Life cycle analyses of engineered organism biofuels can show 50-80% reduction in greenhouse gas emissions compared to fossil fuels, though economic competitiveness depends on petroleum prices.

Synthetic Genomes and Minimal Cells

DNA synthesis advances enable construction of entire microbial genomes from scratch. Craig Venter's team synthesised the 1.08 Mb Mycoplasma mycoides genome using 1078 DNA fragments assembled in yeast and transplanted into an enucleated M. capricolum cell—creating the first synthetic bacterial cell (JCVI-syn1.0, 2010). The subsequent design-and-build of JCVI-syn3.0 with only 473 genes (the minimum essential genome) created cells with the smallest known genome of a self-replicating organism, with 149 genes still of unknown function—revealing how much fundamental cell biology remains unknown. Synthetic yeast chromosomes (Sc2.0 project) are redesigning the 16 S. cerevisiae chromosomes with synthetic design enabling genome-wide recombination for evolution studies.

Examples and Applications

Example 1: Artemisinin Production

The Keasling laboratory engineered S. cerevisiae to produce artemisinic acid—the precursor to artemisinin antimalarial drug—through a 12-step heterologous pathway including mevalonate pathway upregulation, amorphadiene synthase, P450 oxidation, and multiple redox reactions. After 150+ person-years of metabolic engineering, industrial-scale production was handed to Sanofi producing 35-60 tonnes artemisinin per year. The project transformed global artemisinin supply stability, demonstrating that synthetic biology can address neglected disease drug supply chains and won Keasling multiple awards, catalysing follow-on engineered biosynthesis programmes for other antimalarials and cancer drugs.

Example 2: Spider Silk Production

Spider dragline silk is stronger than steel and tougher than Kevlar by mass, yet spiders cannot be farmed (territorial, cannibalise). Synthetic biology transferred spider silk protein genes (MaSp1, MaSp2 from Nephila spiders) to goats, silkworms, E. coli, and yeast for silk protein production. Pioneer Biotech/Bolt Threads and Spiber produce engineered silk proteins in yeast at commercial scale, wet-spun into fibres with tunable properties. AMSilk in Germany produces silk proteins in E. coli for medical device coatings and personal care products. Applications span from luxury textiles to biomedical sutures, tissue engineering scaffolds, and impact-resistant materials.

Example 3: CRISPR Base Editors

David Liu's base editing technology creates single-nucleotide changes without double-strand breaks. Cytosine base editors (CBEs) deaminate cytosine to uracil (read as thymine) within a 4-8 nt editing window using nCas9 nickase fused to deaminase enzyme. Adenine base editors (ABEs) convert adenine to inosine (read as guanine). Together, C-to-T and A-to-G conversions cover approximately 30% of known disease-causing point mutations. Prime editing (2019) extends this to all 12 possible substitution types, small insertions, and deletions. Clinical trials using base editors to correct sickle cell mutations, familiarise PCSK9 variants, and HBV integration are underway—remarkably precise genome editing enabled by protein engineering.

Example 4: Programmable Cell Therapies

SYNTHECON-type approaches engineer T cells with complex decision circuits combining CAR expression, costimulatory domains, suicide genes, and logic gates. 'SYNC' cells express two CARs (for two antigens) with AND gate integration—kill only cells expressing both, reducing healthy tissue damage. SynNotch circuits activate gene expression only when the receptor binds a specific ligand, enabling cell-autonomous sensing and response to tumour-specific combinations of antigens. Kill switches using RQR8 (rituximab-sensitive CD20-like tag on engineered cells) enable rapid elimination of therapeutic cells by rituximab if toxicity occurs. These programmable safety and specificity features are enabling CAR-T cells to tackle solid tumours with higher target diversity.

Example 5: Genetic Biocontainment

Releasing genetically engineered organisms to the environment requires containment strategies preventing environmental spread. Semantic containment evolves organisms requiring unnatural amino acids (UAA) incorporated at essential gene positions—organisms die without chemically synthesised UAA in their medium. Auxotrophy for synthetic compounds unavailable in nature prevents replication outside designated environments. Harvard's MAGE-engineered bacteria have all 321 TAG stop codons reassigned to UAA incorporation—a 3.8 Mb genome replacement providing robust biocontainment while demonstrating feasibility of organism-scale genetic code expansion. Regulatory frameworks for environmental release of contained synthetic organisms are evolving as gene drive and environmental engineering applications advance.

Example 6: Cell-Free Synthetic Biology

Cell-free systems use purified transcription and translation machinery outside living cells to produce proteins or execute genetic circuits without a living organism. PURE system reconstitutes E. coli transcription-translation from 36 purified proteins and is highly customisable. Cell-free systems enable rapid prototyping of genetic circuits (3-8 hours versus days in cells), synthesis of toxic proteins, unnatural amino acid incorporation without live cell engineering, and point-of-care diagnostics (SHERLOCK, DETECTR—cell-free CRISPR-based nucleic acid detection). Freeze-dried cell-free reactions can be rehydrated on field or in low-resource settings, enabling portable biosensors for infectious disease, contaminant detection, and food safety monitoring.

Example 7: Gene Drives

Gene drives are synthetic biology systems that bias inheritance beyond the Mendelian 50% expected frequency, spreading genetic modifications through wild populations. CRISPR homing drives cut wild-type alleles and copy the drive allele through HDR, achieving >90% inheritance. Proposed applications: spreading malaria-refractory genes through Anopheles mosquito populations; suppressing invasive rodent populations on island conservation areas; reducing Aedes aegypti dengue/Zika vector capacity. Ecological risks, cross-border spread, reversibility, and governance are profoundly important; daisy-chain drives (requiring multiple genetic elements only in modified populations to be maintained) and regional drives (restricted to isolated populations) are being developed as risk-mitigating architectures.

Example 8: Engineered Living Materials

Engineered living materials (ELMs) combine synthetic biology with materials science to create materials that grow, self-repair, sense their environment, and evolve. Voigt lab engineered E. coli to produce biofilm proteins forming patterned nanofibre structures with electronic conductivity or controlled mechanical properties through genetic programming of curli fibre composition. Living concrete incorporates photosynthetic cyanobacteria into sand aggregates; bacteria-mineral precipitation strengthens the composite while bacteria remain viable and can mineralise cracks. Silk-based living materials incorporate engineered cells that sense and respond to inputs. ELMs could enable self-healing infrastructure, biological-electronic hybrid devices, and soft robotics powered by living cells.

Try it live

Everything above runs in your browser — open Synthetic Biology: Engineering Living Systems and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.